Navigation Links
Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer
Date:11/5/2011

Carcinoma: Final Data."

A randomized, placebo-controlled Phase 2b clinical trial of JX-594 in patients with hepatocellular carcinoma (HCC) having failed sorafenib (Nexavar®) treatment was recently initiated; this trial (TRAVERSE), conducted globally with Jennerex's partners, is evaluating survival in advanced HCC patients who have either progressed or exhibited intolerance after treatment with sorafenib, the current standard of care.

"These data showing an improvement in overall survival are very encouraging—particularly when coupled with the favorable tolerability profile of JX-594 experienced in this and prior clinical trials. Another therapeutic option to treat patients with HCC, the third leading cause of cancer death globally, is urgently needed," stated Dr. Reid, a clinical investigator on the HEP007 clinical trial.

"The strength of these data—showing a statistically significant benefit in overall survival—gives us great confidence in the potential of JX-594 to benefit patients with liver and other types of cancer world-wide," stated David H. Kirn, M.D., president and chief medical officer of Jennerex.  "Based on these clinical data, and clinical data we've previously published, we are accelerating the development of JX-594. Together with our partners, we're initiating a more expansive late-stage TRAVERSE clinical trial of JX-594 in HCC, and we're moving into Phase 1/2 trials in additional cancer types, including ras mutant and Erbitux-refractory colorectal cancer."

JX-594: A Multi-Mechanistic Approach To Targeting Cancer

JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the shutdown of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the b
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
2. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
7. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
8. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
9. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
10. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
11. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 WABC Radio ... Your Pet with Lorry Young will be hosting California-based ... talk about stem cell therapy in pets. Dr. Harman ... benefits of stem cell therapy for pets suffering from osteoarthritis ... the Regenerative Veterinary Medicine industry forward. , Young has invited ...
(Date:7/25/2014)... IN (PRWEB) July 25, 2014 At ... (FAA) has granted a 60-day extension for the public ... the Special Rule for Model Aircraft established by Congress ... of 2012. The 60-day extension establishes the new deadline ... United States Department of Transportation/FAA notice published in the ...
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
(Date:7/24/2014)... scientists are making progress in devising suitable means ... relies on quantum dotsa kind of artificial atom, ... new study demonstrates that changing the coupling of ... impulses can help better control them. This has ... quantum information units, which would produce faster quantum ...
Breaking Biology Technology:Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3FAA Grants Comment Extension at the Request of AMA 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... DENVER, Dec. 16, 2010 BioSpace launched ... showcasing life sciences companies across Massachusetts. (Logo: ... science employers. Each campaign participant,s logo is added to ... promoted online and at industry events or career fairs. ...
... MADISON, N.J., Dec. 16, 2010 Quest Diagnostics ... provider of diagnostic testing, information and services, today ... Version 2010.2, is 2011/2012 compliant and was certified ... 2010, by the Certification Commission for eligible Health ...
... Gen-Probe Incorporated (Nasdaq: GPRO ) announced ... privately held specialty diagnostics company focused on the transplantation, ... in cash. Gen-Probe acquired GTI from the ... individual investors who include the company,s founders and management. ...
Cached Biology Technology:BioSpace Highlights One of the Nation's Largest Life Science Regions 2Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification 2Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification 3Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification 4Gen-Probe Acquires GTI Diagnostics for $53 Million in Cash 2Gen-Probe Acquires GTI Diagnostics for $53 Million in Cash 3
(Date:7/25/2014)... era, 100,000s of people lived on the land now ... to control the availability of plants they used for ... use fire to maintain desired habitat and natural resources. ... Service,s Pacific Southwest Station, will lead a field ... during the Ecological Society of America,s 99th Annual Meeting, ...
(Date:7/25/2014)... WA Nearly 600 scientists from 25 countries ... Genetics Meeting organized by the Genetics Society of ... Washington in Seattle. The conference will feature close ... research results on topics including gene expression and ... emerging technologies, evolution, aging, and a variety of ...
(Date:7/25/2014)... (SB) is a complex congenital central nervous system ... of the neural tubes during the embryonic phase. ... and fecal incontinence and neurocognitive retardation. Such problems ... of life. Researchers at Ankara Physical Medicine and ... functional performance in children with SB, using the ...
Breaking Biology News(10 mins):Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2
... simple sugar ameliorate Alzheimer's-like disease in mice, according to ... studies are still in the early stages, the findings ... the onset of Alzheimer's disease. , The new studies ... known as inositol--prevented the accumulation of amyloid â deposits, ...
... issue obstructing the productivity of biomedical scientists today is ... belief of some that the lack of "open access" ... productivity. , A survey of 883 biomedical scientists ... Publishing Research Consortium found that aside from ...
... region off the coast of Namibia, researchers have found that ... they contribute to this ocean region. The findings represent a ... after intense fishing in the area in the last few ... University of St. Andrews, and his colleagues in the July ...
Cached Biology News:A sweet solution for Alzheimer's disease? 2A sweet solution for Alzheimer's disease? 3Funding and bureaucracy, not access to journals, are chief obstacles to scientific productivity 2Jellyfish dominate fish in over-harvested Namibian waters 2
...
Mouse monoclonal antibody raised against a full length recombinant ATF3. NCBI Entrez Gene ID = ATF3...
... dsRNA Marker consists of ten double-stranded RNAs, ... 400, 500 and 1,000 base pairs. The ... for determinating sizes of double-stranded RNAs. A ... dsRNA Marker is adjusted to approximately 25 ...
... antibody raised against a partial ... Immunogen: HD (NP_002102, 81 ... recombinant protein with GST tag. ... NM_002111 ...
Biology Products: